Pharm Exec57m
FDA Accepts Supplemental New Drug Application for Teva, Medincell’s Uzedy for Bipolar I Disorder
The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...
Medincell to Present at the TD Cowen 45th Annual Healthcare Conference, March 3-5, 2025, Boston, MA
Christophe Douat, CEO, and Richard Malamut, CMO, will present Medincell’s corporate overview at the TD Cowen 45 th Annual Healthcare Conference on Monday, March 3, 2025, at 9:50am ET. Live webcast and ...
The Pharma Letter9h
FDA accepts Teva and Medincell’s Uzedy sNDA
Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...
Teva, Medincell announce FDA acceptance of sNDA for Uzedy
Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...
FDA accepts Teva's application for Uzedy for bipolar I disorder
The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...
Investing22h
FDA accepts Teva, Medincell's supplemental application for UZEDY as bipolar I disorder treatment
UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...
FDA accepts Teva & Medincell’s UZEDY sNDA for extended-release to treat BP-I
Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...